Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Fiche publication
Date publication
septembre 2012
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR
Lien Pubmed
Résumé
Pemetrexed-based chemotherapy represents the standard of care in first-line treatment of advanced malignant pleural mesothelioma (MPM). However, there are no established predictors of clinical benefit. Pemetrexed inhibits multiple enzymes involved in pyrimidine and purine synthesis, but the main target is thymidylate synthase (TS). After cellular uptake pemetrexed is converted into more effective polyglutamated forms by folylpoly-γ-glutamate synthetase (FPGS). We hypothesized that FPGS and TS protein expressions are associated with clinical outcome after pemetrexed-based chemotherapy.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carboplatin, administration & dosage, Cisplatin, administration & dosage, Female, Follow-Up Studies, Glutamates, administration & dosage, Guanine, administration & dosage, Humans, Male, Mesothelioma, drug therapy, Middle Aged, Neoplasm Staging, Pemetrexed, Peptide Synthases, metabolism, Pleural Neoplasms, drug therapy, Prognosis, Retrospective Studies, Survival Rate, Thymidylate Synthase, metabolism
Référence
J Thorac Oncol. 2012 Sep;7(9):1440-8